



C/2026/2079

7.4.2026

**Prior notification of a concentration**  
**(Case M.12319 – CHARLESBANK / NORDIC CAPITAL / TECOMET / ORCHID)**  
**Candidate case for simplified procedure**

(Text with EEA relevance)

(C/2026/2079)

1. On 25 March 2026, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 <sup>(1)</sup>.

This notification concerns the following undertakings:

- Titan Holdings Topco, LP (United States), controlled by Charlesbank Capital Partners LLC ('Charlesbank', United States),
- Nordic Capital IX Limited (Jersey), ultimately controlled by Nordic Capital Cooperation Group Limited ('Nordic Capital', Jersey),
- A newly created joint venture (the 'JV'), comprising both Tecomet, Inc. ('Tecomet', United States), currently controlled by Charlesbank, and Orchid MPS Holdings, LLC ('Orchid', United States), currently controlled by Nordic Capital.

Charlesbank and Nordic Capital will acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of the JV.

The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are the following:

- Charlesbank is a US private equity firm investing in Business & Consumer Services, Healthcare, Industrial, and Technology. Its subsidiary Tecomet is global contract manufacturing organisation ('CMO') focusing on med-tech (principally orthopaedic) implants, instruments, and cases and trays,
- Nordic Capital is a private equity firm which, through its funds, invests in large and medium sized companies active in a wide range of sectors including healthcare, technology and payments, financial services, and to a lesser extent, consumer and industrial and business services within the EEA and globally. Its subsidiary Orchid is a global CMO focusing on orthopaedic implants and instruments.

3. The business activities of the JV will be the following:

- CMO services for orthopaedic implants and instruments.

4. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified treatment for certain concentrations under Council Regulation (EC) No 139/2004 on the control of concentrations between undertakings <sup>(2)</sup>, it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

5. The Commission invites interested third parties to submit their possible observations on the proposed concentration to the Commission.

<sup>(1)</sup> OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation').

<sup>(2)</sup> OJ C 160, 5.5.2023, p. 1.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.12319 – CHARLESBANK / NORDIC CAPITAL / TECOMET / ORCHID

Observations can be sent to the Commission by email or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Postal address:

European Commission  
Directorate-General for Competition  
Merger Registry  
1049 Bruxelles/Brussel  
BELGIQUE/BELGIË

---